GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cyclopharm Ltd (ASX:CYC) » Definitions » EV-to-Revenue

Cyclopharm (ASX:CYC) EV-to-Revenue : 6.15 (As of May. 06, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cyclopharm's enterprise value is A$162.04 Mil. Cyclopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$26.34 Mil. Therefore, Cyclopharm's EV-to-Revenue for today is 6.15.

The historical rank and industry rank for Cyclopharm's EV-to-Revenue or its related term are showing as below:

ASX:CYC' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.07   Med: 4.84   Max: 16.37
Current: 6.15

During the past 13 years, the highest EV-to-Revenue of Cyclopharm was 16.37. The lowest was 1.07. And the median was 4.84.

ASX:CYC's EV-to-Revenue is ranked worse than
72% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: 3.22 vs ASX:CYC: 6.15

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-06), Cyclopharm's stock price is A$1.80. Cyclopharm's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.28. Therefore, Cyclopharm's PS Ratio for today is 6.34.


Cyclopharm EV-to-Revenue Historical Data

The historical data trend for Cyclopharm's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclopharm EV-to-Revenue Chart

Cyclopharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.01 13.87 7.25 4.00 6.59

Cyclopharm Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.25 - 4.00 - 6.59

Competitive Comparison of Cyclopharm's EV-to-Revenue

For the Medical Devices subindustry, Cyclopharm's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclopharm's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cyclopharm's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cyclopharm's EV-to-Revenue falls into.



Cyclopharm EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cyclopharm's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=162.042/26.339
=6.15

Cyclopharm's current Enterprise Value is A$162.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cyclopharm's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$26.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclopharm  (ASX:CYC) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cyclopharm's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.80/0.284
=6.34

Cyclopharm's share price for today is A$1.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.28.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclopharm EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cyclopharm's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclopharm (ASX:CYC) Business Description

Traded in Other Exchanges
N/A
Address
Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm (ASX:CYC) Headlines

No Headlines